Viyash Scientific Limited has confirmed the dispatch of the Notice of Postal Ballot to seek shareholder approval for the appointment of two new directors and a one-time performance incentive for its Whole-time Director & CEO-Animal Health. The company has completed the dispatch of electronic copies of the notice on Friday, May 29, 2026, to members whose email addresses are registered with the company or depository participants as on the cut-off date of Friday, May 22, 2026. The advertisement confirming the dispatch was published in Financial Express (English) and Nava Telangana (Telugu).

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Amit Jain (DIN: 06917608) and Mr. Abhiroop Jayanthi (DIN: 10354445) as Additional Directors on April 22, 2026. Both individuals are nominees of The Carlyle Group. Their appointments are subject to shareholder approval via Ordinary Resolution within three months of the initial appointment date, specifically by July 21, 2026. Neither director will be entitled to sitting fees or commission but will receive reimbursement of expenses as per company policy.

Performance Incentive Proposal

Shareholders are also asked to approve a Special Resolution for a one-time performance incentive of ₹4 crore for Mr. Rajaram Narayanan (DIN: 02977405). The incentive is proposed in recognition of the company's financial and operational transformation over the last three years, including the successful merger with Viyash Group. The payment is scheduled for the financial year ending March 31, 2027, and is in addition to his existing remuneration approved at the 40th Annual General Meeting held on August 08, 2025.

E-Voting Schedule and Process

The remote e-voting period is scheduled to commence on Saturday, May 30, 2026, at 9.00 a.m. IST and conclude on Sunday, June 28, 2026, at 5.00 p.m. IST. National Securities Depository Limited (NSDL) has been engaged to provide the e-voting facility. The results of the postal ballot are expected to be declared on or before Tuesday, June 30, 2026.

M/s. Nishant Darak and Associates, represented by Mr. Nishant Darak, has been appointed as the Scrutinizer to oversee the postal ballot and e-voting process. The notice has been sent to members electronically in compliance with the Ministry of Corporate Affairs circulars.

Viyash Scientific Limited has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported a significant turnaround in profitability for the fourth quarter on both standalone and consolidated bases, driven by strong revenue growth and operational efficiency improvements. The merger process, approved by all regulatory authorities, is now in effect, with the company focusing on synergy realization over the next 12 months.

Q4 FY26 Consolidated Financial Performance

Viyash Scientific reported a consolidated net profit of ₹663.80 million for the fourth quarter, compared to a net loss of ₹321.80 million in the corresponding period of the previous year. On a standalone basis, the net profit stood at ₹358.10 million against a net loss of ₹193.70 million in Q4 FY25. Consolidated revenue from operations for the quarter came in at ₹9,199.60 million, compared to ₹7,723.10 million in the year-ago period, reflecting strong year-on-year growth. The company's EBITDA for the quarter surged by 63.8% to ₹2,001 million, with the EBITDA margin expanding by 590 basis points to 21.7%.

The gross margin for the quarter improved to 55.1%, up from 52.8% in Q4 FY25. Earnings before tax (EBT) for the quarter were reported at ₹1,252.40 million on a consolidated basis, compared to a loss of ₹366.60 million in the prior year. The net debt position also strengthened significantly, with the Net Debt to LTM EBITDA ratio reducing to 0.2x from 1.0x in FY25.

Annual Performance FY26

Viyash Scientific delivered robust growth for the full fiscal year 2025-26. Total consolidated revenue from operations for FY26 reached ₹34,203.10 million, marking a 13.8% increase over the previous year's ₹30,068.40 million. The company's consolidated net profit for the year stood at ₹2,246.50 million, a sharp rise from ₹157.70 million in FY25.

Annual EBITDA grew by 59.6% to ₹7,025 million, with an EBITDA margin of 20.5%, an improvement of 590 basis points year-on-year. The gross margin for the year was recorded at 54.3%. The company noted that FY26 was a transformative year, marked by the successful integration of facilities and operations, which began to reflect meaningfully in the financial performance through merger synergies.

Operational and Business Updates

The company reported progress across its business segments during the quarter. Formulations revenue grew by 28% year-on-year in Q4 to ₹4,991 million, while APIs revenue increased by 5% to ₹3,836 million. Geographically, Europe and Emerging Markets were key contributors to the growth in formulations.

On the operational front, the company completed 2 regulatory audits and 36 customer audits during the period. It secured regulatory approvals for 4 APIs and 4 Finished Dosage Forms (FDFs) from the USFDA. Additionally, the company launched 5 APIs and 1 FDF in various markets including the USA, MENA, and Canada.